Karyopharm Therapeutics (KPTI) PT Raised to $9 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Karyopharm Therapeutics (KPTI) Present Updated Phase 2 Selinexor Data in Patients with Myelofibrosis
December 13, 2021 5:23 AM ESTKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation highlighting updated data from the Phase 2 ESSENTIAL study, an investigator-sponsored study evaluating single-agent selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with myelofibrosis (MF) previously treated with JAK inhibition. These updated results were presented at the American Society of Hematology (ASH) 2021 Annual Meeting and Exposition taking place in Atlanta, GA on December 11-14, 2021.
"The results presented at ASH this year demonstrate that once weekly single-agent oral selinexor resulted in an... More
